In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Internal Medicine"
DOI: 10.7326/j21-0014
Abstract: SOURCE CITATION Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150-60. 34449183. read more here.
Keywords: tavr edoxaban; vkas composite; edoxaban noninferior; composite adverse ... See more keywords